Craig Thomas Glynn is the CFO & Treasurer at Hancock Jaffe Laboratories Inc.
As the CFO & Treasurer of Hancock Jaffe Laboratories Inc, the total compensation of Mr Glynn at Hancock Jaffe Laboratories Inc is 143,000$. There are 2 executives at Hancock Jaffe Laboratories Inc getting paid more, with Robert A. Berman having the highest compensation of 415,808$.
Mr Glynn is 59, he's been the CFO & Treasurer of Hancock Jaffe Laboratories Inc since . There are 2 older and 1 younger executives at Hancock Jaffe Laboratories Inc. The oldest executive at Hancock Jaffe Laboratories Inc is Dr. Marc H. Glickman, 71, who is the Sr. VP & Chief Medical Officer.
Craig's mailing address filed with the SEC is C/O JAFFE LABORATORIES,, 70 DOPPLER, IRVINE, CA, 92618.
Over the last 6 years, insiders at Hancock Jaffe Laboratories Inc have traded over 1,313,267$ worth of Hancock Jaffe Laboratories Inc stock and bought 39,132 units worth 123,953$ . The most active insiders traders include Holding, S.A. Biodyne、Robert Andrew Berman、Francis Duhay. On average, Hancock Jaffe Laboratories Inc executives and independent directors trade stock every 100 days with the average trade being worth of 3,344,125$. The most recent stock trade was executed by Matthew Jenusaitis on 25 August 2021, trading 1,300 units of HJLI stock currently worth 10,010$.
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
Hancock Jaffe Laboratories Inc executives and other stock owners filed with the SEC include: